HER2-directed ADC: trastuzumab binds HER2, is internalized, and releases deruxtecan (a topoisomerase I inhibitor) causing DNA damage and apoptosis with bystander effect and ADCC. Topoisomerase I is only the intracellular enzymatic target of the payload, not the binding target.